Human electrophysiological and pharmacological properties of XEN-D0101: A novel atrial-selective Kv1.5/IKur inhibitor

John Ford, James Milnes, Erich Wettwer, Torsten Christ, Marc Rogers, Kathy Sutton, David Madge, L. Virág, N. Jost, Zoltan Horvath, Klaus Matschke, A. Varró, Ursula Ravens

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The human electrophysiological and pharmacological properties of XEN-D0101 were evaluated to assess its usefulness for treating atrial fibrillation (AF). XEN-D0101 inhibited Kv1.5 with an IC50 of 241 nM and is selective over non-target cardiac ion channels (IC50 Kv4.3, 4.2 μM; hERG, 13 μM; activated Nav1.5, >100 μM; inactivated Nav1.5, 34 μM; Kir3.1/3.4, 17 μM; Kir2.1, >>100 μM). In atrial myocytes from patients in sinus rhythm (SR) and chronic AF, XEN-D0101 inhibited non-inactivating outward currents (Ilate) with IC50 of 410 and 280 nM, respectively, and peak outward currents (Ipeak) with IC50 of 806 and 240 nM, respectively. Whereas Ilate is mainly composed of IKur, Ipeak consists of IKur and Ito. Therefore, the effects on Ito alone were estimated from a double-pulse protocol where IKur was inactivated (3.5 μM IC50 in SR and 1 μM in AF). Thus, inhibition of Ipeak is because of IKur reduction and not Ito. XEN-D0101 significantly prolonged the atrial action potential duration at 20%, 50%, and 90% of repolarization (AF tissue only) and significantly elevated the atrial action potential plateau phase and increased contractility (SR and AF tissues) while having no effect on human ventricular action potentials. In healthy volunteers, XEN-D0101 did not significantly increase baseline- and placebo-adjusted QTc up to a maximum oral dose of 300 mg. XEN-D0101 is a Kv1.5/IKur inhibitor with an attractive atrial-selective profile.

Original languageEnglish
Pages (from-to)408-415
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume61
Issue number5
DOIs
Publication statusPublished - May 2013

Fingerprint

Atrial Fibrillation
Inhibitory Concentration 50
Pharmacology
Action Potentials
Ion Channels
Muscle Cells
XEN-D0101
Healthy Volunteers
Placebos

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Human electrophysiological and pharmacological properties of XEN-D0101 : A novel atrial-selective Kv1.5/IKur inhibitor. / Ford, John; Milnes, James; Wettwer, Erich; Christ, Torsten; Rogers, Marc; Sutton, Kathy; Madge, David; Virág, L.; Jost, N.; Horvath, Zoltan; Matschke, Klaus; Varró, A.; Ravens, Ursula.

In: Journal of Cardiovascular Pharmacology, Vol. 61, No. 5, 05.2013, p. 408-415.

Research output: Contribution to journalArticle

Ford, John ; Milnes, James ; Wettwer, Erich ; Christ, Torsten ; Rogers, Marc ; Sutton, Kathy ; Madge, David ; Virág, L. ; Jost, N. ; Horvath, Zoltan ; Matschke, Klaus ; Varró, A. ; Ravens, Ursula. / Human electrophysiological and pharmacological properties of XEN-D0101 : A novel atrial-selective Kv1.5/IKur inhibitor. In: Journal of Cardiovascular Pharmacology. 2013 ; Vol. 61, No. 5. pp. 408-415.
@article{65487e5706ab484e97236476367e2132,
title = "Human electrophysiological and pharmacological properties of XEN-D0101: A novel atrial-selective Kv1.5/IKur inhibitor",
abstract = "The human electrophysiological and pharmacological properties of XEN-D0101 were evaluated to assess its usefulness for treating atrial fibrillation (AF). XEN-D0101 inhibited Kv1.5 with an IC50 of 241 nM and is selective over non-target cardiac ion channels (IC50 Kv4.3, 4.2 μM; hERG, 13 μM; activated Nav1.5, >100 μM; inactivated Nav1.5, 34 μM; Kir3.1/3.4, 17 μM; Kir2.1, >>100 μM). In atrial myocytes from patients in sinus rhythm (SR) and chronic AF, XEN-D0101 inhibited non-inactivating outward currents (Ilate) with IC50 of 410 and 280 nM, respectively, and peak outward currents (Ipeak) with IC50 of 806 and 240 nM, respectively. Whereas Ilate is mainly composed of IKur, Ipeak consists of IKur and Ito. Therefore, the effects on Ito alone were estimated from a double-pulse protocol where IKur was inactivated (3.5 μM IC50 in SR and 1 μM in AF). Thus, inhibition of Ipeak is because of IKur reduction and not Ito. XEN-D0101 significantly prolonged the atrial action potential duration at 20{\%}, 50{\%}, and 90{\%} of repolarization (AF tissue only) and significantly elevated the atrial action potential plateau phase and increased contractility (SR and AF tissues) while having no effect on human ventricular action potentials. In healthy volunteers, XEN-D0101 did not significantly increase baseline- and placebo-adjusted QTc up to a maximum oral dose of 300 mg. XEN-D0101 is a Kv1.5/IKur inhibitor with an attractive atrial-selective profile.",
author = "John Ford and James Milnes and Erich Wettwer and Torsten Christ and Marc Rogers and Kathy Sutton and David Madge and L. Vir{\'a}g and N. Jost and Zoltan Horvath and Klaus Matschke and A. Varr{\'o} and Ursula Ravens",
year = "2013",
month = "5",
doi = "10.1097/FJC.0b013e31828780eb",
language = "English",
volume = "61",
pages = "408--415",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Human electrophysiological and pharmacological properties of XEN-D0101

T2 - A novel atrial-selective Kv1.5/IKur inhibitor

AU - Ford, John

AU - Milnes, James

AU - Wettwer, Erich

AU - Christ, Torsten

AU - Rogers, Marc

AU - Sutton, Kathy

AU - Madge, David

AU - Virág, L.

AU - Jost, N.

AU - Horvath, Zoltan

AU - Matschke, Klaus

AU - Varró, A.

AU - Ravens, Ursula

PY - 2013/5

Y1 - 2013/5

N2 - The human electrophysiological and pharmacological properties of XEN-D0101 were evaluated to assess its usefulness for treating atrial fibrillation (AF). XEN-D0101 inhibited Kv1.5 with an IC50 of 241 nM and is selective over non-target cardiac ion channels (IC50 Kv4.3, 4.2 μM; hERG, 13 μM; activated Nav1.5, >100 μM; inactivated Nav1.5, 34 μM; Kir3.1/3.4, 17 μM; Kir2.1, >>100 μM). In atrial myocytes from patients in sinus rhythm (SR) and chronic AF, XEN-D0101 inhibited non-inactivating outward currents (Ilate) with IC50 of 410 and 280 nM, respectively, and peak outward currents (Ipeak) with IC50 of 806 and 240 nM, respectively. Whereas Ilate is mainly composed of IKur, Ipeak consists of IKur and Ito. Therefore, the effects on Ito alone were estimated from a double-pulse protocol where IKur was inactivated (3.5 μM IC50 in SR and 1 μM in AF). Thus, inhibition of Ipeak is because of IKur reduction and not Ito. XEN-D0101 significantly prolonged the atrial action potential duration at 20%, 50%, and 90% of repolarization (AF tissue only) and significantly elevated the atrial action potential plateau phase and increased contractility (SR and AF tissues) while having no effect on human ventricular action potentials. In healthy volunteers, XEN-D0101 did not significantly increase baseline- and placebo-adjusted QTc up to a maximum oral dose of 300 mg. XEN-D0101 is a Kv1.5/IKur inhibitor with an attractive atrial-selective profile.

AB - The human electrophysiological and pharmacological properties of XEN-D0101 were evaluated to assess its usefulness for treating atrial fibrillation (AF). XEN-D0101 inhibited Kv1.5 with an IC50 of 241 nM and is selective over non-target cardiac ion channels (IC50 Kv4.3, 4.2 μM; hERG, 13 μM; activated Nav1.5, >100 μM; inactivated Nav1.5, 34 μM; Kir3.1/3.4, 17 μM; Kir2.1, >>100 μM). In atrial myocytes from patients in sinus rhythm (SR) and chronic AF, XEN-D0101 inhibited non-inactivating outward currents (Ilate) with IC50 of 410 and 280 nM, respectively, and peak outward currents (Ipeak) with IC50 of 806 and 240 nM, respectively. Whereas Ilate is mainly composed of IKur, Ipeak consists of IKur and Ito. Therefore, the effects on Ito alone were estimated from a double-pulse protocol where IKur was inactivated (3.5 μM IC50 in SR and 1 μM in AF). Thus, inhibition of Ipeak is because of IKur reduction and not Ito. XEN-D0101 significantly prolonged the atrial action potential duration at 20%, 50%, and 90% of repolarization (AF tissue only) and significantly elevated the atrial action potential plateau phase and increased contractility (SR and AF tissues) while having no effect on human ventricular action potentials. In healthy volunteers, XEN-D0101 did not significantly increase baseline- and placebo-adjusted QTc up to a maximum oral dose of 300 mg. XEN-D0101 is a Kv1.5/IKur inhibitor with an attractive atrial-selective profile.

UR - http://www.scopus.com/inward/record.url?scp=84877590480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877590480&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e31828780eb

DO - 10.1097/FJC.0b013e31828780eb

M3 - Article

C2 - 23364608

AN - SCOPUS:84877590480

VL - 61

SP - 408

EP - 415

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 5

ER -